Recognition and response
MD Sermorelin encounters an antibody puzzle
A peptide modeled on a natural hormone still drew an immune response in a childhood study. The children’s growth complicates the obvious conclusion.
Antibodies in a childhood growth study
In a 1993 study of 60 children with growth hormone deficiency, GHRH(1-29)-NH2 was given for 6 months. Nearly all the children developed antibodies to GHRH. No growth hormone antibodies were detected, and the GHRH antibodies did not correlate with growth. By 9 months after treatment stopped, they had almost disappeared.
I’d assumed that resemblance to a native hormone ensured a fairly uneventful reception. That assumption was too tidy. Here was an immune response, clearly detected, alongside a growth response that the antibodies failed to explain.
To my ear, “natural” does far too much persuasive work around sermorelin. Sermorelin is a synthetic, amidated fragment of growth hormone-releasing hormone, or GHRH. Its relationship to the native hormone explains its activity at a receptor. The antibody finding adds a different question: how does the body recognize repeated exposure?
Growth over 12 to 24 months
The Lanes and Carrillo childhood study followed prepubertal children with growth hormone deficiency during 12 to 24 months of treatment. Several responders developed GHRH antibodies, which did not appear to interfere with growth. The study reported no side effects or changes in glucose and lipid levels during therapy.
An antibody is a protein that recognizes a target. Detection alone leaves its practical effect unsettled. I’d mistaken antibody detection for an automatic failure story; these growth findings forced a more interesting possibility, in which recognition and continuing response coexist.
That is a limited reassurance. These were children with a diagnosed deficiency, followed for a particular treatment question. I would welcome adult follow-up that brought the same interest in repeated exposure to the much broader claims now made for sermorelin. The growth and safety notes pursue the clinical findings in more detail.
The signal the pituitary recognizes
GHRH normally prompts the pituitary gland to release growth hormone, or GH. Sermorelin contains the first 29 amino acids of GHRH, retaining activity at the GHRH receptor. Stimulation raises cellular cAMP and activates machinery for GH synthesis and release; somatostatin and IGF-1 feedback remain involved.
That arrangement has an appealing logic. Walker’s editorial argues for preserving the body’s own regulation rather than supplying GH directly. Walker wins me over on physiology, though a clinical outcome still needs to be attached to the argument. The antibody observations in children are particularly useful because they describe what happened after sustained exposure to the peptide.
The research notes follow that distinction through GHRH analogs, adult trials and compounds that act through a different receptor.
Adult use
The childhood record gives sermorelin a substantive medical history. Adult anti-aging claims reach into a different population and a different set of goals. A published caution about GH secretagogues and aging judged that use insufficiently supported; long-term wellness benefit remains unproven.
Give me the small, awkward finding over an elegant sales argument. The antibody puzzle offers no verdict on adult treatment. Continued exposure, and the people receiving it, now occupy my curiosity.
For the historical quantities that studies actually administered, there is a sermorelin dosing ledger. The source list includes the childhood papers, the adult experiments and the regulatory documents.